JPH09503788A - 治療用送達組成物及びその使用方法 - Google Patents
治療用送達組成物及びその使用方法Info
- Publication number
- JPH09503788A JPH09503788A JP51203195A JP51203195A JPH09503788A JP H09503788 A JPH09503788 A JP H09503788A JP 51203195 A JP51203195 A JP 51203195A JP 51203195 A JP51203195 A JP 51203195A JP H09503788 A JPH09503788 A JP H09503788A
- Authority
- JP
- Japan
- Prior art keywords
- copolymer
- nucleic acid
- molecular weight
- gene
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.非イオン性ブロックコポリマーと混合した核酸機能を改変し得る化合物を 含むヒト又は動物を処置するための治療用組成物であって、前記ブロックコポリ マーは次式を有する該治療用組成物。 HO(C2H4O)b(C3H6O)a(C2H4O)bH (式中、前記コポリマーのポリオキシプロピレン部分の分子量は約750から約15, 000であり、前記コポリマーのポリオキシエチレン部分の分子量は前記コポリマ ーの約1%から約50%である。) 2.前記コポリマーのポリオキシプロピレン部分の分子量が約2,250から約15, 000であり、前記コポリマーのポリオキシエチレン部分の分子量が前記コポリマ ーの約5%から約20%である請求項1に記載の組成物。 3.前記コポリマーのポリオキシプロピレン部分の分子量が約3,250から約15, 000であり、前記コポリマーのポリオキシエチレン部分の分子量が前記コポリマ ーの約5%から約20%である請求項1に記載の組成物。 4.前記コポリマーがCRL−8131又はCRL−8142である請求項1に記載の 組成物。 5.前記の核酸配列機能を改変し得る化合物が、遺伝子、オリゴヌクレオチド 、アンチセンスオリゴヌクレオチド、トリプレックスDNA化合物及びリボザイ ムからなる群から選択される請求項1に記載の組成物。 6.約0.1重量%から約5重量%の界面活性剤と約0.5容量%から約5容量%の 低分子量アルコールを更に含む請求項7に記載の組成物。 7.前記界面活性剤がトゥイーン80であり、前記アルコールがエタノールであ る請求項6に記載の組成物。 8.発現ベクターを更に含み、前記の核酸配列機能を改変し得る化合物が該発 現ベクターに含まれる核酸配列であり、該発現ベクターは核酸配列を発現するこ とができる請求項7に記載の組成物。 9.非イオン性ブロックコポリマーと混合した核酸機能を改変し得る化合物を 含む組成物をヒト又は動物に投与する段階を含む、核酸配列機能を改変し得る化 合物をヒト又は動物に送達する方法であって、前記ブロックコポリマーは次式を 有する該方法。 HO(C2H4O)b(C3H6O)a(C2H4O)bH (式中、前記コポリマーのポリオキシプロピレン部分の分子量は約750から約15, 000であり、前記コポリマーのポリオキシエチレン部分の分子量は前記コポリマ ーの約1%から約50%である。) 10.前記コポリマーのポリオキシプロピレン部分の分子量が約2,250から約1 5,000であり、前記コポリマーのポリオキシエチレン部分の分子量が前記コポリ マーの約5%から約20%である請求項9に記載の方法。 11.前記コポリマーのポリオキシプロピレン部分の分子量が約3,250から約1 5,000であり、前記コポリマーのポリオキシエチレン部分の分子量がコポリマー 前記の約5%から約20%である請求項9に記載の方法。 12.前記コポリマーがCRL−8131又はCRL−8142である請求項9に記載 の方法。 13.前記の核酸配列機能を改変し得る化合物が、遺伝子、オリゴヌクレオチ ド、アンチセンスオリゴヌクレオチド、トリプレックスDNA化合物及びリボザ イムからなる群から選択される請求項9に記載の方法。 14.約0.1重量%から約5重量%の界面活性剤と約0.5容量%から約5容量% の低分子量アルコールを更に含む請求項9に記載の方法。 15.前記界面活性剤がトゥイーン80であり、前記アルコールがエタノールで ある請求項14に記載の方法。 16.発現ベクターを更に含み、前記の核酸配列機能を改変し得る化合物が該 発現ベクターに含まれる核酸配列であり、該発現ベクターは核酸配列を発現する ことができる請求項9に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13827193A | 1993-10-15 | 1993-10-15 | |
US138,271 | 1993-10-15 | ||
PCT/US1994/011594 WO1995010265A1 (en) | 1993-10-15 | 1994-10-12 | Therapeutic delivery compositions and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09503788A true JPH09503788A (ja) | 1997-04-15 |
JP3819422B2 JP3819422B2 (ja) | 2006-09-06 |
Family
ID=22481270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51203195A Expired - Fee Related JP3819422B2 (ja) | 1993-10-15 | 1994-10-12 | 治療用送達組成物及びその使用方法 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0723440B1 (ja) |
JP (1) | JP3819422B2 (ja) |
KR (1) | KR100218140B1 (ja) |
AT (1) | ATE230260T1 (ja) |
AU (1) | AU8076494A (ja) |
DE (1) | DE69431959T2 (ja) |
DK (1) | DK0723440T3 (ja) |
ES (1) | ES2189808T3 (ja) |
WO (1) | WO1995010265A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1181937A3 (en) | 1994-08-09 | 2004-02-04 | Cytrx Corporation | Novel vaccine adjuvant and vaccine |
US5656611A (en) * | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
US6040295A (en) | 1995-01-13 | 2000-03-21 | Genemedicine, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
US7002027B1 (en) | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
US5789244A (en) | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US6392069B2 (en) | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
US6673914B1 (en) | 1998-01-22 | 2004-01-06 | John Wayne Cancer Institute | Human tumor-associated gene |
KR100360827B1 (ko) * | 1999-08-14 | 2002-11-18 | 주식회사 삼양사 | 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법 |
US6875748B2 (en) | 2000-04-21 | 2005-04-05 | Vical Incorporated | Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
EP1232758A1 (fr) * | 2001-02-19 | 2002-08-21 | Aventis Pasteur | Polynucléotide formulé en vue d'un transfert intracellulaire amélioré |
AU2002366809A1 (en) | 2001-12-20 | 2003-07-09 | Schering-Plough Corporation | Syn3 compositions and methods |
CN100429220C (zh) | 2003-06-04 | 2008-10-29 | 坎基股份有限公司 | 用于干扰素治疗的方法和组合物 |
SI3721888T1 (sl) | 2013-02-05 | 2023-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Tarčne terapije proti CD47 za zdravljenje infekcijske bolezni |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3308458A1 (de) * | 1983-03-10 | 1984-09-13 | Behringwerke Ag, 3550 Marburg | Verfahren zur adjuvierung von vaccinen |
IT1191608B (it) * | 1985-02-01 | 1988-03-23 | Zambon Spa | Composizione farmaceutica e forme farmaceutiche che la contengono |
AU6334586A (en) * | 1986-05-15 | 1987-12-01 | Emory University | Composition and method for treating a thrombus and embolus |
US5037644A (en) * | 1986-10-27 | 1991-08-06 | Cetus Corporation | Pharmaceutical compositions of recombinant interleukin-2 and formulation processes |
US5221495A (en) * | 1990-04-13 | 1993-06-22 | Colgate-Palmolive Company | Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions |
HUT67762A (en) * | 1991-03-19 | 1995-04-28 | Cytrx Corp | Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof |
WO1993008845A1 (en) * | 1991-11-08 | 1993-05-13 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
-
1994
- 1994-10-12 AU AU80764/94A patent/AU8076494A/en not_active Abandoned
- 1994-10-12 DE DE1994631959 patent/DE69431959T2/de not_active Expired - Fee Related
- 1994-10-12 EP EP19940931827 patent/EP0723440B1/en not_active Expired - Lifetime
- 1994-10-12 KR KR1019960701930A patent/KR100218140B1/ko not_active IP Right Cessation
- 1994-10-12 DK DK94931827T patent/DK0723440T3/da active
- 1994-10-12 JP JP51203195A patent/JP3819422B2/ja not_active Expired - Fee Related
- 1994-10-12 ES ES94931827T patent/ES2189808T3/es not_active Expired - Lifetime
- 1994-10-12 WO PCT/US1994/011594 patent/WO1995010265A1/en active IP Right Grant
- 1994-10-12 AT AT94931827T patent/ATE230260T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0723440A4 (en) | 1997-06-11 |
ES2189808T3 (es) | 2003-07-16 |
DK0723440T3 (da) | 2003-02-24 |
DE69431959D1 (de) | 2003-02-06 |
JP3819422B2 (ja) | 2006-09-06 |
KR100218140B1 (ko) | 1999-09-01 |
AU8076494A (en) | 1995-05-04 |
EP0723440A1 (en) | 1996-07-31 |
EP0723440B1 (en) | 2003-01-02 |
WO1995010265A1 (en) | 1995-04-20 |
ATE230260T1 (de) | 2003-01-15 |
DE69431959T2 (de) | 2003-11-06 |
KR960704534A (ko) | 1996-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6933286B2 (en) | Therapeutic delivery compositions and methods of use thereof | |
US20020123476A1 (en) | Therapeutic delivery compositions and methods of use thereof | |
JP3819422B2 (ja) | 治療用送達組成物及びその使用方法 | |
US5712257A (en) | Topically active compositions of mismatched dsRNAs | |
EP0683669B1 (en) | Methods and compositions of a polymer (poloxamer) for cell repair | |
US20030138407A1 (en) | Therapeutic methods for nucleic acid delivery vehicles | |
JPH09508530A (ja) | 核酸を含む組成物、その調製および使用 | |
EP0303516B1 (en) | Topically active compositions of double-stranded RNAs | |
PT88266B (pt) | Processo para a prepracao de composicoes farmaceuticas parenterais contendo dsrna | |
US5811088A (en) | Antiinfective compounds and methods of use | |
AU739916B2 (en) | Rotavirus vaccine formulations | |
KR20050042230A (ko) | 티모신 알파 1 펩티드/중합체 결합체 | |
JP2002501499A (ja) | 免疫調節剤の用途 | |
US6482803B1 (en) | Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A | |
CA2174122C (en) | Therapeutic delivery compositions and methods of use thereof | |
US7202225B1 (en) | Therapeutic delivery compositions and methods of use thereof | |
US20040063637A1 (en) | Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy | |
JP2005500340A (ja) | 治療のための送達用組成物およびその使用方法 | |
AU2002329679A1 (en) | Therapeutic delivery compositions and methods of use thereof | |
US20060062855A1 (en) | Therapeutic calcium phosphate particles for use in inhibiting expression of a gene | |
JP2002500175A (ja) | ヒト免疫不全ウイルスに対して使用する多分枝ペプチド構築物含有リポソーム | |
CN111920825B (zh) | 一种女性生殖道抗hpv的组合物及其应用 | |
JP2007137771A (ja) | 炎症性疾患治療剤、およびその利用 | |
WO2023154478A1 (en) | Methods of assessing cancer | |
AU724058B2 (en) | Topically active compositions of double-stranded RNAs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050705 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051005 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060105 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060516 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060615 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090623 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100623 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110623 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110623 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120623 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120623 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130623 Year of fee payment: 7 |
|
LAPS | Cancellation because of no payment of annual fees |